Silence Therapeutics to receive $4M milestone payment from Hansoh

Silence Therapeutics announced that it will receive a $4M cash payment from Hansoh Pharmaceutical following the achievement of two undisclosed preclinical milestones. Silence and Hansoh entered a collaboration in October 2021 to develop siRNAs leveraging Silence’s proprietary mRNAi Gold platform for three undisclosed targets. Under the terms of the agreement, Silence has exclusive rights to the first two targets in all territories except the China region. Hansoh has the exclusive option to license rights to those two targets in Greater China, Hong Kong, Macau and Taiwan, and global rights to the third target. Hansoh made a $16M upfront payment to Silence and the company is eligible to receive up to $1.3B in development, regulatory and commercial milestones. Silence is also eligible to receive royalties tiered from low double-digit to mid-teens on Hansoh net product sales.